*Refresh the page if the below document does not appear.
SC accepts cognizance of Rs 1000 crore Pharma Doctor Nexus
The messy issue of pharmaceutical companies bribing doctors with various freebies reached the Supreme Court corridors once again, when allusion was made during the hearing of the UCPMP matter to the recent IT raid on makers of Dolo 650.
Pharma MSMEs urge health ministry to remove mandatory QR code on APIs as of January 2023
Pharma MSMEs have urged the Union Health Ministry to repeal the Drugs Rules, 2022, which require a QR code on the label of all active pharmaceutical ingredients manufactured in India, at each level packaging, beginning in January next year to enable tracking and tracing.
Drug companies ask govt from revoking ITC on soon-to-expire Covid medications
To reduce impending losses, the drug industry has asked the government to consider waiving the reversal of input tax credit (ITC) on soon to expire Covid drugs and their raw materials, including active pharmaceutical ingredients (APIs).
Products in US being recalled by Glenmark, Strides Pharma, & Cipla
USFDA announced the recall of 1,032 bottles of Prednisone tablets, a medication used to treat a variety of conditions such as asthma, allergic reactions, arthritis, and inflammatory bowel disease, among others.
Novavax Covid-19 vaccine Adjuvanted receives expanded approval in US
US Food and Drug Administration has granted expanded emergency use authorization for its Covid-19 vaccine Adjuvanted for adolescents aged 12-17 years, making it the first protein based Covid-19 jab approved in the US.
In order to avoid irregularities in price fixation, KSRPO pushes for one formulation, one MRP
One formulation and one MRP (maximum retail price) have been advocated for by the Karnataka State Registered Pharmacists Organization (KSRPO) in order to prevent price fixation irregularities.
Axsome promotes Auvelity as potentially revolutionary depression treatment after receiving FDA approval
The deprivation of effective treatment options
for major depression is well documented. The
FDA has now approved Axsome Therapeutics’
Auvelity, the first oral rapid-acting treatment
for MDD.
